[1]
Hébert J,Muccilli A,Wennberg RA,Tang-Wai DF, Autoimmune Encephalitis and Autoantibodies: A Review of Clinical Implications. The journal of applied laboratory medicine. 2022 Jan 5
[PubMed PMID: 34996085]
[2]
Kanniah G,Kumar R,Subramaniam G, Anti-NMDA Receptor Encephalitis: A Challenge in Psychiatric Settings. Journal of psychiatric practice. 2022 Jan 6
[PubMed PMID: 34989350]
[3]
Solomon T,Michael BD,Smith PE,Sanderson F,Davies NW,Hart IJ,Holland M,Easton A,Buckley C,Kneen R,Beeching NJ,National Encephalitis Guidelines Development and Stakeholder Groups., Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines. The Journal of infection. 2012 Apr;
[PubMed PMID: 22120595]
[4]
Titulaer MJ,McCracken L,Gabilondo I,Armangué T,Glaser C,Iizuka T,Honig LS,Benseler SM,Kawachi I,Martinez-Hernandez E,Aguilar E,Gresa-Arribas N,Ryan-Florance N,Torrents A,Saiz A,Rosenfeld MR,Balice-Gordon R,Graus F,Dalmau J, Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet. Neurology. 2013 Feb;
[PubMed PMID: 23290630]
[5]
Armangue T,Spatola M,Vlagea A,Mattozzi S,Cárceles-Cordon M,Martinez-Heras E,Llufriu S,Muchart J,Erro ME,Abraira L,Moris G,Monros-Giménez L,Corral-Corral Í,Montejo C,Toledo M,Bataller L,Secondi G,Ariño H,Martínez-Hernández E,Juan M,Marcos MA,Alsina L,Saiz A,Rosenfeld MR,Graus F,Dalmau J,Spanish Herpes Simplex Encephalitis Study Group., Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. The Lancet. Neurology. 2018 Sep;
[PubMed PMID: 30049614]
Level 2 (mid-level) evidence
[6]
Cabezudo-García P,Mena-Vázquez N,Estivill Torrús G,Serrano-Castro P, Response to immunotherapy in anti-IgLON5 disease: A systematic review. Acta neurologica Scandinavica. 2020 Apr;
[PubMed PMID: 31853949]
Level 1 (high-level) evidence
[7]
Al-Diwani A,Handel A,Townsend L,Pollak T,Leite MI,Harrison PJ,Lennox BR,Okai D,Manohar SG,Irani SR, The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. The lancet. Psychiatry. 2019 Mar;
[PubMed PMID: 30765329]
Level 1 (high-level) evidence
[8]
Ariño H,Armangué T,Petit-Pedrol M,Sabater L,Martinez-Hernandez E,Hara M,Lancaster E,Saiz A,Dalmau J,Graus F, Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology. 2016 Aug 23;
[PubMed PMID: 27466467]
[9]
van Sonderen A,Thijs RD,Coenders EC,Jiskoot LC,Sanchez E,de Bruijn MA,van Coevorden-Hameete MH,Wirtz PW,Schreurs MW,Sillevis Smitt PA,Titulaer MJ, Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016 Oct 4;
[PubMed PMID: 27590293]
[10]
van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, Lancaster E, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Graus F, Dalmau J, Titulaer MJ. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016 Aug 2:87(5):521-8. doi: 10.1212/WNL.0000000000002917. Epub 2016 Jul 1
[PubMed PMID: 27371488]
[11]
Irani SR,Pettingill P,Kleopa KA,Schiza N,Waters P,Mazia C,Zuliani L,Watanabe O,Lang B,Buckley C,Vincent A, Morvan syndrome: clinical and serological observations in 29 cases. Annals of neurology. 2012 Aug;
[PubMed PMID: 22473710]
Level 3 (low-level) evidence
[12]
Spatola M,Petit-Pedrol M,Simabukuro MM,Armangue T,Castro FJ,Barcelo Artigues MI,Julià Benique MR,Benson L,Gorman M,Felipe A,Caparó Oblitas RL,Rosenfeld MR,Graus F,Dalmau J, Investigations in GABA{sub}A{/sub} receptor antibody-associated encephalitis. Neurology. 2017 Mar 14;
[PubMed PMID: 28202703]
[13]
Petit-Pedrol M,Armangue T,Peng X,Bataller L,Cellucci T,Davis R,McCracken L,Martinez-Hernandez E,Mason WP,Kruer MC,Ritacco DG,Grisold W,Meaney BF,Alcalá C,Sillevis-Smitt P,Titulaer MJ,Balice-Gordon R,Graus F,Dalmau J, Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. The Lancet. Neurology. 2014 Mar;
[PubMed PMID: 24462240]
Level 2 (mid-level) evidence
[14]
Lancaster E,Lai M,Peng X,Hughes E,Constantinescu R,Raizer J,Friedman D,Skeen MB,Grisold W,Kimura A,Ohta K,Iizuka T,Guzman M,Graus F,Moss SJ,Balice-Gordon R,Dalmau J, Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet. Neurology. 2010 Jan;
[PubMed PMID: 19962348]
Level 2 (mid-level) evidence
[15]
Laurido-Soto O,Brier MR,Simon LE,McCullough A,Bucelli RC,Day GS, Patient characteristics and outcome associations in AMPA receptor encephalitis. Journal of neurology. 2019 Feb;
[PubMed PMID: 30560455]
[16]
Tobin WO,Lennon VA,Komorowski L,Probst C,Clardy SL,Aksamit AJ,Appendino JP,Lucchinetti CF,Matsumoto JY,Pittock SJ,Sandroni P,Tippmann-Peikert M,Wirrell EC,McKeon A, DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014 Nov 11;
[PubMed PMID: 25320100]
[17]
Carvajal-González A,Leite MI,Waters P,Woodhall M,Coutinho E,Balint B,Lang B,Pettingill P,Carr A,Sheerin UM,Press R,Press R,Lunn MP,Lim M,Maddison P,Meinck HM,Vandenberghe W,Vincent A, Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain : a journal of neurology. 2014 Aug;
[PubMed PMID: 24951641]
[18]
Hamid SHM,Whittam D,Saviour M,Alorainy A,Mutch K,Linaker S,Solomon T,Bhojak M,Woodhall M,Waters P,Appleton R,Duddy M,Jacob A, Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. JAMA neurology. 2018 Jan 1;
[PubMed PMID: 29131884]
[19]
Gresa-Arribas N,Planagumà J,Petit-Pedrol M,Kawachi I,Katada S,Glaser CA,Simabukuro MM,Armangué T,Martínez-Hernández E,Graus F,Dalmau J, Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology. 2016 Jun 14;
[PubMed PMID: 27170573]
[20]
Gaig C,Compta Y, Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Current opinion in neurology. 2019 Jun;
[PubMed PMID: 30694925]
Level 3 (low-level) evidence
[21]
Restrepo-Martínez M,Espinola-Nadurille M,López-Hernández JC,Martínez V,Téllez-Martínez JA,Bustamante-Gómez PA,Bautista-Gómez P,Bayliss L,Ramírez-Bermúdez J, [Neuropsychiatric aspects of anti-NMDA receptor encephalitis]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993). 2021 Oct-Dec
[PubMed PMID: 34904561]
[22]
Graus F,Titulaer MJ,Balu R,Benseler S,Bien CG,Cellucci T,Cortese I,Dale RC,Gelfand JM,Geschwind M,Glaser CA,Honnorat J,Höftberger R,Iizuka T,Irani SR,Lancaster E,Leypoldt F,Prüss H,Rae-Grant A,Reindl M,Rosenfeld MR,Rostásy K,Saiz A,Venkatesan A,Vincent A,Wandinger KP,Waters P,Dalmau J, A clinical approach to diagnosis of autoimmune encephalitis. The Lancet. Neurology. 2016 Apr;
[PubMed PMID: 26906964]
[23]
Gresa-Arribas N,Titulaer MJ,Torrents A,Aguilar E,McCracken L,Leypoldt F,Gleichman AJ,Balice-Gordon R,Rosenfeld MR,Lynch D,Graus F,Dalmau J, Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. The Lancet. Neurology. 2014 Feb;
[PubMed PMID: 24360484]
Level 2 (mid-level) evidence
[25]
Xu Q,Wang Q,Han J,Mao F,Zeng S,Chen S,Zhao C,Gu M,Li Z,Fu X,Luo X,Huang Y, Central Hypoventilation Is a Key Risk Factor for Mechanical Ventilation During the Acute Phase of Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Frontiers in neurology. 2021;
[PubMed PMID: 34795627]